Abstract
Background
HE4 and CA 125 are identified as a potential biomarker for the detection of some diseases with fibrosis.
Objectives
The purpose of this pilot study was to evaluate the value of human epididymis protein 4 (HE4) and cancer antigen-125 (CA-125) in otosclerosis patients.
Material and methods
The study population consisted of 60 people (30 otosclerosis patients, 30 control group). We collected blood samples for HE4 and CA-125 levels. Serum HE4 and CA-125 levels were measured by enzyme-linked immunosorbent assay (ELISA). We compared the results between otosclerosis patients and the normal subject. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was performed to evaluate the diagnostic value.
Results
There was no differences in CA-125 level between the otosclerosis (20.3 U/mL [10.4-42.1] and control group (19.3 U/mL [15.3-49.8]) (p > 0.05). HE4 level was significantly higher in the otosclerosis group (60.9 pmol/L [32.1-101.8])] than the control group (25.3 pmol/L [12.4-91.9]) (p < 0.001). The AUC in ROC analysis of HE4 was 0.768 (p < 0.001).
Conclusions and significance
Serum HE4 level may be a useful biomarker in otosclerosis. Further studies with a larger number of patients are required to confirm our pilot results.
Chinese Abstract
背景
HE4 和 CA 125 被确定为检测某些纤维化疾病的潜在生物标志物。
目的
本项先导研究的目的是评估人类附睾蛋白 4 (HE4) 和癌症抗原 125 (CA-125) 对于耳硬化症患者的价值。
材料和方法
研究人群包括 60 人(30 名耳硬化症患者, 30 名对照者)。我们收集血液样本以检测 HE4 和 CA-125 水平。通过酶联免疫吸附试验 (ELISA) 测量血清 HE4 和 CA-125 水平。我们比较了耳硬化症患者和正常受试者的结果。接收者操作特性 (ROC) 曲线的线下面积 (AUC) 用来评估诊断价值。
结果
耳硬化症组的CA-125水平(20.3U/mL [10.4-42.1])和对照组的CA-125水平(19.3U/mL [15.3-49.8])之间没有差异(p > 0.05)。耳硬化症组的HE4水平(60.9pmol/L [32.1-101.8])显著高于对照的HE4水平组(25.3pmol/L [12.4-91.9])(p < 0.001)。HE4的ROC分析中的AUC为0.768(p < 0.001)。
结论和意义
血清HE4水平可能是耳硬化症的有用生物标志物。需要对更多患者进行进一步研究以证实我们的初步结果。
Keywords:
Authors’ contributions
BG and DE conceived the study. DE was involved in participant recruitment.BG performed the statistical analyses, wrote and drafted the manuscript.
Disclosure statement
The authors report no conflict of interest.